BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas.

ABSTRACT:

Background

Sentinel node biopsy (SNB) is an important step in melanoma staging and prognostication. It is commonly performed for patients with intermediate thickness melanomas, based on clinicopathological features. However, only 20-25% of patients eventually demonstrate nodal involvement. The aim of this study was to evaluate whether tissue biomarkers with links to melanoma biology, together with clinicopathological parameters, could aid in the prediction of sentinel node involvement and improve selection of patients for SNB. In addition, we examined the role of these clinical or biological markers in disease outcome.

Methods

We collected a case-control cohort of 140 intermediate thickness (Breslow 0,9-4,0mm) melanoma patients with or without SNB involvement matched for age

SUBMITTER: Manninen AA 

PROVIDER: S-EPMC6490950 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature